RSV Season – Palivizumab (Synagis) and Nirsevimab Guidance

From: Dr. Danielle Zerr, Medical Director of Infection Prevention and Seattle Children’s Pharmacy and Therapeutics Committee

Seattle Children’s began administering palivizumab (Synagis) on Nov 2 due to increasing RSV rates. We ask that community providers with patients who need Synagis provide it directly rather than referring patients to Seattle Children’s, due to capacity constraints at the hospital. Eligibility for palivizumab and nirsevimab follows the CDCs updated guidance.

A reminder about Nirsevimab

• Nirsevimab is available at our hospital campus in limited supply for inpatients nearing discharge and outpatients with established subspecialty care at Seattle Children’s who do not have access through their PCP.
• Nirsevimab is not available at our Urgent Care sites.

For more information

• CDC’s updated guidance (10-23-23) – addresses limited availability of product
• RSV Update | Washington Vaccine Association (10-12-23)
• AAP’s Nirsevimab FAQs
• Find family-facing resources about RSV at the end of the article “What Parents and Caregivers Should Know About RSV” (On the Pulse, 10-24-23)